LoPreCol: Evaluation of the Contribution of Low-pressure Intra-abdominal Insufflation for Laparoscopic Colic Resection

Sponsor
Institut Paoli-Calmettes (Other)
Overall Status
Recruiting
CT.gov ID
NCT04112654
Collaborator
(none)
128
1
2
39
3.3

Study Details

Study Description

Brief Summary

The laparoscopic surgery requires gas insufflation in the peritoneal cavity and the operator chooses the intraabdominal insufflation pressure. In general, during a conventional laparoscopy, this pressure is 12 to 15 mmHg. The reduction of the intra-abdominal pressure minimizes the parietal trauma due to the insufflation and could lead to a reduction of the postoperative pains and could allow an earlier recovery. In this study, the investigator propose to evaluate the benefits of a low pressure insufflation (6-8 mmHg) with pressure-controlled insufflator in patients with a mild or malignant colon pathology requiring surgical colic resection. The main objective of the study is to demonstrate that the laparoscopic colic resection at low pressure reduces the theoretical hospital stay of one day compared to the conventional laparoscopy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Conventional pressure laparoscopy
  • Procedure: Low pressure laparoscopy
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
128 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Prospective Randomized Evaluation of the Contribution of Low-pressure Intra-abdominal Insufflation for Laparoscopic Colic Resection
Actual Study Start Date :
Jun 29, 2020
Anticipated Primary Completion Date :
Jun 29, 2023
Anticipated Study Completion Date :
Sep 29, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Conventional laparoscopy

Laparoscopy realized at the conventional pressure (12-15 mmHg) using conventional insufflator.

Procedure: Conventional pressure laparoscopy
Conventional pressure laparoscopy using conventional insufflator AirSeal®

Experimental: Low pressure laparoscopy

Laparoscopy realized at low pressure (6-8mmHg) using pressure-controlled insufflator AirSeal®

Procedure: Low pressure laparoscopy
Low pressure laparoscopy using pressure-controlled insufflator AirSeal®

Outcome Measures

Primary Outcome Measures

  1. The theoretical hospital stay [from hospitalization day until hospital discharge, assessed up to 15 days]

    The theoretical hospital stay in days (calculated from the day of the surgery to the theoretical day of discharge according to predefined exit criteria)

Secondary Outcome Measures

  1. Morbidity rate [20 days post surgery]

    Morbidity evaluated according Dindo-clavien classification

  2. Mortality rate [20 days post surgery]

    Dead patient listing

  3. GastroIntestinal-Quality-of-Life Index (GIQLI) [20 days and 3 months post surgery]

    GastroIntestinal-Quality-of-Life Index (GIQLI) questionnaire, 36 questions, each containing 4 answers equating to a score ranging from 0 (least desirable answer) to 4 (most desirable answer). Total score range 0-144.

  4. Short Form Health (SF12) score [20 days and 3 months post surgery]

    This questionnaire is an abbreviated version of the "Medical Outcomes Study Short-Form General Health Survey" (SF-36) contains only 12 items out of 36 with minimum score 0 (bad quality life) and maximum score at 100 (good quality life).

  5. Pain score using self-report pain assessment tool (EVA) [From surgery to hospital discharge assessed up to 15 days, at 20 days and at 3 months post surgery]

    EVA measures the intensity of pain on a scale of 0 (no pain) to 10 (maximum pain imaginable)

  6. Intestinal transit recovery time frame [From surgery to transit recovery assessed up to 15 days]

    Period duration from surgery to intestinal gas recovery time (in days)

  7. Nausea and vomiting incidence [From surgery to hospital discharge assessed up to 15 days]

    Nausea and vomiting listing

  8. Analgesic treatment incidence [From surgery to 3 months post surgery]

    Non-morphine and morphine analgesic consumption

  9. Real hospitalization duration [From hospitalization day until hospital discharge assessed up to 15 days]

    Real hospitalization duration (actual patient discharge date based on non-medical criteria)

  10. Rehospitalization number [from hospital discharge assessed up to 15 days to 3 months post surgery]

    Rehospitalization listing

  11. Differential cost of patient care [From surgery to hospital discharge assessed up to 15 days]

    According operating room occupation and real hospital stay

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Colic lesion justifying surgical resection by segmental colectomy,

  • Surgery proposed by laparoscopy,

  • Body mass index (BMI) ≤30 kg/m2,

  • Written informed consent signed by the patient,

  • Patient affiliated to the national French statutory healthcare insurance, system or beneficiary of this regimen.

Exclusion Criteria:
  • Probable realization of a stoma during the procedure,

  • Robot-assisted approach,

  • Contraindication to laparoscopic surgery,

  • Pregnant or likely to be pregnant,

  • Patient deprived of liberty or placed under the authority of a tutor,

  • Patient considered geographically socially or psychologically unable to comply with the study procedure and the medical follow-up.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Institut Paoli Calmettes Marseille Bouches Du Rhone France 13009

Sponsors and Collaborators

  • Institut Paoli-Calmettes

Investigators

  • Principal Investigator: Cecile DE CHAISEMARTIN, MD, Institut Paoli-Calmettes

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Institut Paoli-Calmettes
ClinicalTrials.gov Identifier:
NCT04112654
Other Study ID Numbers:
  • LOPRECOL-IPC 2017-02
  • LOPRECOL-IPC 2017-02
First Posted:
Oct 2, 2019
Last Update Posted:
Mar 9, 2022
Last Verified:
Mar 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 9, 2022